Probicobacter tablete s PylopassTM, ki se veže s Helicobacter pylori in prispeva k njenemu izločanju iz telesa.
Z dodatkom ekstrakta brokolija ter z vitamini A, C, B12 in cinkom.
Navodilo za uporabo (odrasli): 1 tableta na dan z malo vode. Pred obrokom, ločeno od antibiotikov ali zaviralcev protonske črpalke (H.pylori eradikacijska terapija).
Ne uporabljati pri alergiji na mlečne beljakovine. Ni podatkov o varni uporabi med nosečnostjo in dojenjem, zato uporabe nosečnicam in doječim mamicam ne priporočamo.
Viri:
Lactobacillus reuteri PylopassTM
⦁ Mehling H, Busjahn A, Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013 Aug 2;5 (8):3062-73. doi: 10.3390/nu5083062.
⦁ Holz C, Busjahn A, Mehling H, Arja S, Boettner M, Habibi H, Land C. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. ⦁ Probiotics Antimicrob Proteins. 2015 Jun; 7(2):91-100 doi: ⦁ 10.1007/s12602-014-9181-3
⦁ Uspenskiy Yu.P, Fomin Yu. A, Ivanov S.V, Menaker I.O. Evolution in eradication therapy of HP -associated diseases: beyond the standards? Russian scientific publication in Gastroenterology No 17,2016
⦁ Parolova Ni, Komienko EA, Antonov PV, Egorov Mikhail Gorbunov EF, Dmitrienko MA. An innovative approach in the treatment of H. pylori infection in children.
⦁ Pop Muresan IA, Liviu Pop L, Dumitrascu DL, Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Gastroenterology. 2019. DOI: 10.15386/mpr-1375.
⦁ Buckley et al. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutrition (2018) 4:48 https://doi.org/10.1186/s40795-018-0257-4
Tong JL, ⦁ Ran ZH, ⦁ Shen J, ⦁ Zhang CX, ⦁ Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007 Jan 15;25(2):155-68.